Antibodies for Use in Identifying And/or Scoring Prostate Cancer and Androgen Receptor-Dependent Gene Expression Control

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes antibodies and siRNAs that can modify the activity of the enzyme lysine-specific demethylase 1 (LSD1). The invention provides diagnostic tools (notably anti-LSD1 antibodies) for identifying and assessing the severity of prostate cancer based on LSD1 levels. It also covers the use of these antibodies and/or siRNAs, alone or in combination with monoamine oxidase inhibitors, as pharmaceuticals to control androgen receptor (AR)-dependent gene expression, which plays a central role in prostate cancer and other AR-influenced tissues. By targeting LSD1, the invention enables both precise molecular diagnostics and therapeutic intervention for prostate cancer and potentially other AR-related disorders.

Use CasesContent extracted from patent full text and abstract with AI.

• Immunohistochemical diagnosis of prostate cancer using anti-LSD1 antibodies to identify aggressive or high-risk carcinomas.
• Stratifying prostate cancer patients based on the risk of disease progression by quantifying LSD1 expression.
• Development of pharmaceutical treatments for prostate cancer by inhibiting or modulating LSD1 activity using antibodies, siRNAs, or their combinations.
• Controlling androgen receptor-dependent gene expression in tissues such as prostate and testis for therapeutic purposes.
• Potential research tools for high-throughput loss-of-function studies using siRNAs targeting LSD1.
• Therapeutic modulation of LSD1 activity in other hormone-responsive tissues or cancers where AR and LSD1 are implicated.

BenefitsContent extracted from patent full text and abstract with AI.

• Enables reliable and specific identification of aggressive prostate cancers, improving patient stratification for treatment.
• Offers both diagnostic and therapeutic (theranostic) applications through the same molecular targets (anti-LSD1 antibodies and siRNAs).
• Allows discrimination between progressive and non-progressive prostate cancers, reducing overtreatment and focusing therapy where most needed.
• Provides novel pharmaceutical compositions for controlling AR-dependent gene expression, targeting a key regulatory step in prostate cancer biology.
• Can be used in combination with existing therapies, such as monoamine oxidase inhibitors, for enhanced efficacy.
• Offers a molecular approach that may be less susceptible to the variability and subjectivity of traditional histopathological scoring systems like Gleason grading.
• Applicable to both clinical and research settings, broadening its potential impact.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to antibodies for use for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical and diagnostical compositions comprising such antibodies. The invention also relates to a method for identifying and/or scoring prostate carcinomas. Furthermore, the invention relates to the use of at least one siRNA ("short interfering RNA") and/or at least one anti-LSD1 antibody for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal or for the manufacture of a medicament for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal. The invention also relates to a pharmaceutical composition for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one siRNA and/or at least one anti-LSD1 antibody suitable for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal. The invention also relates to a method for controlling the androgen receptor-dependent gene expression in a mammal, said process comprising the step of administering to said mammal, on a suitable route, an effective dose of a pharmaceutical composition modulating an activity of the lysine-specific demethylase (LSD1) in a mammal.